SECURITIES | 2026-10-28

Section 17(a) of the Securities Act: The SEC’s Fraud Weapon That Does Not Always Require Scienter — Aaron v. SEC Explained for California Issuers

Section 17(a) of the Securities Act of 1933 is the SEC’s broad antifraud tool for securities offerings. Under Aaron v. SEC, two of its three prongs require no proof of intent at all — negligence is enough. For California issuers, underwriters, and executives, that lower bar makes §17(a) a more dangerous enforcement provision than Rule 10b-5 in many cases. This guide explains how it works.

When most people think of securities fraud, they think of §10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 , which require proof of scienter — an intent to deceive or recklessness. But the SEC has a second, older antifraud weapon aimed at the offer or sale of securities: Section 17(a) of

Securities-offering fraud can be pursued by the SEC under more than one statute, and the differences between them decide how hard the Commission must work to win. The most important of those differences is the state of mind the government must prove. Rule 10b-5 demands scienter. Section 17(a) of the Securities Act, by contrast, demands scienter for only one of its three prongs — the other two can be proven with ordinary negligence. This article explains the structure of §17(a), the Supreme Court’s decision in Aaron v. SEC, why the provision matters in offerings, and how it fits alongside Rule 10b-5 and the private-litigation landscape.

What Section 17(a) Prohibits

Section 17(a) makes it unlawful, in the offer or sale of any security, by use of interstate commerce or the mails, to do any of three things. Under §17(a)(1), to employ any device, scheme, or artifice to defraud. Under §17(a)(2), to obtain money or property by means of an untrue statement of a material fact or a material omission. And under §17(a)(3), to engage in any transaction, practice, or course of business that operates or would operate as a fraud or deceit upon the purchaser. The three prongs overlap substantially with Rule 10b-5(a), (b), and (c), but §17(a) applies specifically to the offer or sale side and, as Aaron held, carries different mental-state requirements across its prongs.

Aaron v. SEC: The Scienter Split

In Aaron v. SEC, 446 U.S. 680 (1980), the Supreme Court resolved what each prong requires. It held that §17(a)(1) — which speaks of a "device, scheme, or artifice to defraud" — requires scienter, because that language connotes intentional wrongdoing. But §17(a)(2) and §17(a)(3) do not. The Court reasoned that §17(a)(2)’s focus on obtaining money or property "by means of" an untrue statement, and §17(a)(3)’s focus on a practice that "operates ... as a fraud," describe the effect of the conduct rather than the actor’s intent. Accordingly, the SEC can establish a violation of §17(a)(2) or §17(a)(3) by showing only negligence. This holding makes §17(a) a materially easier provision for the government to win on than Rule 10b-5 in offering cases.

Why the Negligence Standard Matters

Scienter is often the hardest element to prove in a securities-fraud case. It requires evidence that the defendant acted with intent to deceive or with recklessness so extreme it approximates intent. Negligence, by contrast, asks only whether the defendant failed to exercise reasonable care — a far lower and more readily provable bar. In a capital raise gone wrong, an executive or underwriter who did not intend to mislead, but who made a careless material misstatement in an offering document, can still face liability under §17(a)(2) or §17(a)(3). The negligence prongs thus reach honest-but-careless conduct that Rule 10b-5 would not. For issuers, this means the diligence behind every representation in an offering is itself a defense — or, if lacking, a vulnerability.

Section 17(a) Reaches Only the Offer or Sale

A key limit distinguishes §17(a) from Rule 10b-5. Section 17(a) applies only to fraud "in the offer or sale" of securities — the issuer’s or seller’s side of a transaction. Rule 10b-5, by contrast, reaches fraud "in connection with the purchase or sale" of securities, covering both buyers and sellers. As a result, §17(a) is the natural fit for enforcement arising out of securities offerings — IPOs, private placements, bond issuances, and the marketing of investment products — where the defendant is on the selling side. Where the alleged fraud concerns a purchase, or market conduct unconnected to an offer or sale by the defendant, Rule 10b-5 is the applicable tool.

No Private Right of Action Under §17(a)

A critical practical point: most federal courts, including the Ninth Circuit, have held that there is no implied private right of action under §17(a). Private investors generally cannot sue under §17(a); the provision is enforced by the SEC (and, for criminal violations, the Department of Justice). This mirrors the Supreme Court’s reluctance to imply private remedies that Congress did not write. Private plaintiffs pursuing offering fraud instead rely on §11 and §12(a)(2) of the Securities Act and on Rule 10b-5. Section 17(a)’s significance, therefore, is almost entirely in the enforcement arena — which is precisely where its negligence prongs give the government an advantage.

Section 17(a) Versus Rule 10b-5: A Side-by-Side

The two provisions are best understood together. Rule 10b-5: reaches the "purchase or sale" of any security; requires scienter for all theories; supports both SEC enforcement and a private right of action. Section 17(a): reaches only the "offer or sale"; requires scienter only for §17(a)(1), with negligence sufficing for §17(a)(2) and §17(a)(3); supports SEC enforcement but generally no private suit. In an offering-fraud enforcement action, the SEC commonly pleads both — Rule 10b-5 and all three §17(a) prongs — so that even if it cannot prove scienter, it can still prevail on the §17(a) negligence prongs. That strategic layering is why §17(a) is so consequential for defendants.

Materiality Still Governs

The negligence standard lowers the mental-state bar, but it does not eliminate the requirement that a misstatement or omission be material. A fact is material if there is a substantial likelihood that a reasonable investor would consider it important in deciding whether to invest — the standard drawn from TSC Industries v. Northway and Basic Inc. v. Levinson. An immaterial inaccuracy, however careless, does not violate §17(a). Materiality is therefore a central battleground even under the negligence prongs: the defense that a challenged statement was true, was not misleading in context, or concerned an immaterial detail remains fully available. The negligence standard concerns how the defendant acted, not whether the statement mattered.

Remedies in a §17(a) Enforcement Action

When the SEC establishes a §17(a) violation, the available remedies are substantial: injunctions against future violations, disgorgement of ill-gotten gains with prejudgment interest, civil monetary penalties, and — for individuals — officer-and-director bars and industry bars. Because the negligence prongs can support these remedies without proof of intent, a defendant who prevails on the scienter question under Rule 10b-5 and §17(a)(1) may still face injunctive relief, disgorgement, and penalties under §17(a)(2) or §17(a)(3). Understanding this is important to any settlement calculus: conceding or losing the negligence prongs can carry consequences nearly as serious as a scienter-based finding.

The Diligence Defense

Because the §17(a) negligence prongs turn on whether the defendant exercised reasonable care, the strongest protection is a documented record of diligence. For an issuer or underwriter, that means a rigorous process behind every representation in an offering: verifying facts, reconciling financial statements, maintaining a defensible due-diligence file, and ensuring that disclosures are reviewed by qualified professionals. A defendant who can show it took reasonable steps to confirm the accuracy of its statements has a genuine defense to a negligence claim. Conversely, the absence of any meaningful diligence is itself evidence of negligence. Building and preserving that record before an offering closes is the practical core of §17(a) risk management.

Why This Matters to California Issuers and Executives

California’s technology, life-sciences, and entertainment sectors generate a steady stream of capital raises — venture financings, IPOs, follow-on offerings, token and investment-product marketing, and private placements. Each is an "offer or sale" squarely within §17(a)’s reach, and each puts officers, directors, and sometimes underwriters and advisers within the Commission’s potential crosshairs. Because the SEC can prevail on the §17(a) negligence prongs without proving intent, California issuers cannot assume that a lack of fraudulent intent will defeat an enforcement action arising from an offering. The realistic exposure is defined by whether the offering disclosures were careful and accurate, not merely whether they were honest.

Frequently Asked Questions

What is Section 17(a) of the Securities Act?

It is the antifraud provision (15 U.S.C. §77q(a)) that prohibits fraud in the offer or sale of securities. It has three prongs: §17(a)(1) (device, scheme, or artifice to defraud), §17(a)(2) (obtaining money or property by a material misstatement or omission), and §17(a)(3) (a practice that operates as a fraud or deceit).

Does Section 17(a) require proof of intent?

Only for one prong. Under Aaron v. SEC (1980), §17(a)(1) requires scienter, but §17(a)(2) and §17(a)(3) require only negligence. The SEC can prove those two prongs without showing the defendant intended to deceive anyone.

How is §17(a) different from Rule 10b-5?

Rule 10b-5 reaches the "purchase or sale" of securities and requires scienter for all theories, and it supports a private right of action. Section 17(a) reaches only the "offer or sale," requires scienter only for §17(a)(1), and generally supports no private suit — it is an SEC enforcement tool.

Can investors sue under Section 17(a)?

Generally no. Most courts, including the Ninth Circuit, hold there is no implied private right of action under §17(a). Private investors pursuing offering fraud rely on §11 and §12(a)(2) of the Securities Act and on Rule 10b-5 instead.

Why does the negligence standard matter so much?

Scienter is usually the hardest element to prove. Negligence asks only whether the defendant failed to exercise reasonable care, a far lower bar. An honest-but-careless material misstatement in an offering document can violate §17(a)(2) or §17(a)(3) even though it would not violate Rule 10b-5.

Does a careless statement violate §17(a) even if it was immaterial?

No. The misstatement or omission must still be material — something a reasonable investor would consider important (TSC Industries v. Northway; Basic v. Levinson). The negligence standard lowers the mental-state bar but does not eliminate the materiality requirement.

What remedies can the SEC obtain under §17(a)?

Injunctions, disgorgement with prejudgment interest, civil monetary penalties, and officer-and-director or industry bars for individuals. Because the negligence prongs can support these remedies, a defendant who defeats the scienter claims may still face serious consequences.

How can an issuer defend against a §17(a) negligence claim?

By showing it exercised reasonable care — a documented due-diligence process behind every representation, verification of facts and financials, and professional review of disclosures. A strong diligence record is a genuine defense to a negligence claim; its absence is itself evidence of negligence.

The "In the Offer or Sale" Requirement in Practice

Because §17(a) reaches only fraud "in the offer or sale" of a security, a recurring question is whether the challenged conduct is sufficiently connected to an offer or sale by the defendant. The phrase is read broadly — it covers the marketing and solicitation leading up to a sale, not merely the closing — but it still requires a nexus between the fraud and a selling activity. Conduct that occurs entirely after a sale is complete, or that concerns a purchase rather than a sale, falls outside §17(a) and must be pursued, if at all, under Rule 10b-5. This boundary matters for structuring an enforcement theory: the SEC will frame the defendant’s role as part of the distribution or solicitation of the securities to bring the conduct within §17(a), while a defense will probe whether the defendant actually offered or sold anything. In offerings with multiple participants — issuer, underwriter, selling agents, finders — the "offer or sale" analysis is applied participant by participant.

Section 17(a) and Criminal Exposure

Section 17(a) is primarily an SEC civil enforcement provision, but willful violations can also be prosecuted criminally under the Securities Act’s penalty provisions. Criminal liability, however, requires willfulness — a mental state far higher than the negligence that suffices for a civil §17(a)(2) or §17(a)(3) claim. The result is a layered risk: the same offering misstatement might support a civil §17(a) negligence claim by the SEC, a scienter-based civil claim under §17(a)(1) and Rule 10b-5, and, where the evidence shows willful misconduct, a criminal referral. Defendants therefore cannot treat a §17(a) inquiry as purely civil from the outset; the facts that establish negligence for civil purposes sit on a continuum with the intent evidence that drives scienter and criminal exposure, and an early assessment of where the conduct falls on that continuum shapes the entire defense strategy.

Layered Liability With Rule 10b-5 and the Securities Act

In a typical offering-fraud enforcement action, §17(a) rarely stands alone. The SEC commonly pleads it alongside Rule 10b-5 (for scienter-based fraud reaching purchases and sales) and, where applicable, invokes the registration and prospectus-liability framework of §11 and §12(a)(2) of the Securities Act that private plaintiffs also use. For individual defendants, the SEC may add control-person allegations under §20(a) of the Exchange Act and aiding-and-abetting theories available to the Commission. The practical effect is that a single offering can generate a web of overlapping theories with different mental-state requirements. A defendant who can defeat scienter still faces the §17(a) negligence prongs; a defendant who can show reasonable diligence attacks those prongs at their root. Mapping which theory carries which burden — and where the evidence is strongest and weakest — is the core of defending an offering-fraud case, and it is why §17(a)’s negligence prongs so often become the decisive battleground.

Settlement Dynamics Under the Negligence Prongs

The §17(a) negligence prongs also shape how enforcement actions resolve. Because the SEC can prevail without proving intent, a defendant confident of defeating scienter cannot assume the whole case will collapse; the Commission retains a viable path to injunctive relief, disgorgement, and penalties on a negligence theory. This asymmetry pushes many offering-fraud matters toward settlement, often on terms that resolve the negligence prongs through a neither-admit-nor-deny consent without any scienter finding. For the defendant, the calculus is whether the diligence record is strong enough to defeat even a negligence claim at trial, or whether a negotiated resolution that avoids a scienter-based judgment — with its collateral consequences for private litigation and licensing — is the better outcome. Counsel weigh the strength of the materiality and diligence defenses against the cost and uncertainty of litigating the negligence prongs to verdict, and that weighing frequently determines whether a case settles early or proceeds. Because a neither-admit-nor-deny resolution on the negligence prongs still carries real consequences — penalties, disgorgement, and sometimes bars — the defense treats the diligence record not as a formality but as the single most valuable asset it can bring to those negotiations.

Related Guides

For related reading, see our guide on the limits on private securities-fraud liability under Central Bank and Stoneridge and our securities and corporate governance practice overview. In an offering-fraud enforcement action, §17(a)’s negligence prongs are often the government’s strongest theory.

Speak With a California Securities Attorney

If you are an issuer, officer, director, underwriter, or adviser facing SEC scrutiny arising from a securities offering, Section 17(a)’s negligence prongs may expose you to liability even without any intent to deceive. Trembach Law Firm analyzes §17(a) and Rule 10b-5 exposure, evaluates the diligence record, and advises on enforcement strategy. Call (818) 514-7680 to discuss your matter with an attorney. Anatolii Trembach holds an LL.M. and is admitted to the California Bar.

This article provides general information about federal securities law and is not legal advice. Enforcement exposure is fact-specific. Consult a qualified securities attorney about your particular situation.

Contact Trembach Law Firm at (818) 514-7680 for a confidential consultation.

Trembach Law Firm | 27001 Agoura Road, Suite 350, Calabasas, CA 91301